Revolutionizing
Cancer
Treatment

Dr. Anderson is an MIT professor and an expert in Nano-based Drugs and Cancer Immunology. His work has led to the first methods for rapid synthesis, formulation, analysis, and biological evaluation of large libraries of biomaterials for use in medical devices, cell therapy, and drug delivery. In particular, the advanced drug delivery systems he has developed provide new methods for nanoparticle drug delivery.

Dr. Langer is an MIT Institute professor (the highest honor that can be awarded to a faculty member) and an expert in biotechnology and engineering. He has over 1,440 issued and pending patents worldwide. He served as Chairman of the FDA’s SCIENCE BOARD (it’s highest advisory board) from 1999-2002. In 2015, Dr. Langer received the Queen Elizabeth Prize for Engineering, the world’s largest engineering prize. He has also received the Charles Stark Draper Prize (sometimes referred to as the engineering Nobel Prize).

Mr. Matussiere has worked until 2017 and for more than twenty years as an investment banker for Société Générale, Citigroup and BNP Paribas, primarily out of London. His focus was on the sales and marketing of structured products, mainly in the credit space. Since 2017, Pierre has become an active Angel investor and fundraiser -through his FCA regulated company M Finance- focusing on sectors such as hospitality, leasing of transport equipment, Healthtech, residential and commercial properties and Biotech. Pierre graduated in 1995 from HEC in Paris.

Dr. Micol has been President and co-founder CEO of Combined Therapeutics since 2016. Previously, he held several positions across the Institut Mérieux group: ABlinc (USA), Shantha Biotechnics (India), Transgene (China and France). Dr. Micol is an entrepreneur with affiliations to six famous universities (MIT in US, LSE in UK, Paris VI, Paris V, Paris Dauphine in France and Global LBS in UK). Additionally he helped to set up the first reference center for primary immunodeficiency in France in 2005.

Dr. VanCott is the Chief Technology & Strategy Officer for Catalent Cell & Gene Therapy, a CDMO manufacturing viral vectors for gene and cell therapies based in the US and Europe. He is responsible for strategically enhancing and augmenting CMC services to meet the market demand of increasingly complex cell and gene therapy products. He also leads the product development and internal R&D teams. Prior to this, he was the CEO for 10 years at another Maryland-based CMO/CRO (ABL) where he was responsible for the strategic international growth of the company. He has been involved in virus and biologic product development for over 25 years. He has a PhD in physical chemistry and started his career as a Captain in the US Army stationed at Walter Reed Army Institute of Research (WRAIR) studying and developing HIV vaccines for international deployment from initial construction through preclinical development and GMP manufacturing to clinical trials.